Skip to main content
European Commission logo
español español
CORDIS - Resultados de investigaciones de la UE
CORDIS
CORDIS Web 30th anniversary CORDIS Web 30th anniversary
Contenido archivado el 2024-05-24

Quality of life following adherence therapy for people disabled by schizophrenia and their carers (QUATRO)

Objetivo

Ant psychotic medication has well-established effectiveness in the treatment of people with schizophrenia. However, adherence to medication is a very common problem, and non-adherence increases the risk of relapse disability, and poor quality of life. The "Quality of Life following Adherence Therapy for People Disabled by Schizophrenia and their Carers" study is a randomised controlled trial and will investigate the effectiveness and cost effectiveness of adherence therapy designed to improve quality of life among schizophrenic patients and their carers. The study is expected to contribute to evidence-based practice in the care for people who suffer from schizophrenia, and their carers, across Europe.

Convocatoria de propuestas

Data not available

Régimen de financiación

CSC - Cost-sharing contracts

Coordinador

KING'S COLLEGE LONDON
Aportación de la UE
Sin datos
Dirección
De Crespigny Park, Denmark Hill
SE5 8AF LONDON
Reino Unido

Ver en el mapa

Coste total
Sin datos

Participantes (3)